Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|July 20, 2002
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial)Hans-Jürgen Stellbrink, Jan van Lunzen, Michael Westby, et al.
The Journal of Antimicrobial Chemotherapy|February 19, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen, Heidy Hendra, Martin Vogel, et al.
Nature Biotechnology|February 23, 2016
Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificityJanet Karpinski, Ilona Hauber, Jan Chemnitz, et al.
AIDS Research and Therapy|November 16, 2019
Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)Guido Schäfer, Christian Hoffmann, Keikawus Arasteh, et al.
AIDS Research and Human Retroviruses|June 12, 2008
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccineSanjay Mehendale, Jan van Lunzen, Nathan Clumeck, et al.
AIDS (London, England)|April 2, 2025
Dolutegravir plus lamivudine downregulates cellular stress responses versus three-drug HIV RegimensVictoria Rios-Vazquez, Wilhelm A J W Vos, Marc J T Blaauw, et al.
Viruses|April 27, 2024
Cardiometabolic Differences in People Living with HIV Receiving Integrase Strand Transfer Inhibitors Compared to Non-nucleoside Reverse Transcriptase Inhibitors: Implications for Current ART StrategiesWilhelm A J W Vos, Nadira Vadaq, Vasiliki Matzaraki, et al.
JCI Insight|February 25, 2021
Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cellsWouter A van der Heijden, Lisa Van de Wijer, Farid Keramati, et al.
The Lancet. Infectious Diseases|November 6, 2015
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority studyAnthony Mills, Jose R Arribas, Jaime Andrade-Villanueva, et al.
Frontiers in Immunology|May 6, 2021
The Architecture of Circulating Immune Cells Is Dysregulated in People Living With HIV on Long Term Antiretroviral Treatment and Relates With Markers of the HIV-1 Reservoir, Cytomegalovirus, and Microbial TranslocationLisa Van de Wijer, Wouter A van der Heijden, Rob Ter Horst, et al.
Pageof 12